Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | VENICE I: MRD response with venetoclax in R/R CLL

Arnon Kater • 20 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Venetoclax

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, gives an update on the VENICE I Phase III study (NCT02756611) looking at measurable residual disease (MRD) response with venetoclax monotherapy in R/R chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Arnon Kater

2:28
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
Arnon Kater • 6 Oct 2023
1:46
Overcoming T-cell dysfunction
Arnon Kater • 6 Oct 2023
0:53
The future of CLL treatment
Arnon Kater • 6 Oct 2023
2:17
EPCORE CLL-1: epcoritamab in patients with R/R CLL & Richter's transformation
Arnon Kater • 6 Oct 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals